Key result
Bariatric surgery is linked to improved NAFLD fibrosis scores and reduced hepatic steatosis.
Why the study?
Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and metabolic syndrome and causes inflammation, insulin resistance, and cardiovascular complications, motivating evaluation of bariatric surgery effects on hepatic function.
Does bariatric surgery improve non-invasive biochemical markers of hepatic steatosis and fibrosis in morbidly obese patients?
Population
64 obese patients undergoing bariatric surgery
Comparison
Biochemical hepatic parameters before and one year after bariatric surgery
Design
Prospective cohort study
Authors
Loading...
Bariatric surgery significantly improves non-invasive biochemical markers of hepatic steatosis and fibrosis in morbidly obese patients at one year.
Cohort (n=72)
No
Does bariatric surgery improve non-invasive biochemical markers of hepatic steatosis and fibrosis in morbidly obese patients?
Absolute Event Rate: -1.66% vs -0.9%
p-value: p=<0.0001
Bariatric surgery significantly improves non-invasive biochemical markers of hepatic steatosis and fibrosis in morbidly obese patients at one year.
Toman et al. (2021) conducted a cohort in Morbid obesity with non-alcoholic fatty liver disease (NAFLD) (n=72). Bariatric surgery vs. Pre-surgery baseline was evaluated on NAFLD fibrosis score (p=<0.0001). Bariatric surgery significantly improved the NAFLD liver fibrosis score (median -0.90 to -1.66, P<0.0001) and reduced hepatic steatosis one year post-intervention in morbidly obese patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: